Results and discussions We corroborate that CMS1 and CMS4 subtypes showed higher levels of immune and stromal infiltration than CMS2-3 subtypes. Several CD molecules have been found to be under-expressed in tumour vs. normal tissues that have a protective effect. Interestingly, when stratifying by subtypes, they showed the better accuracy discriminating between good and poor prognosis patients in the CMS4 subtype. Significant functions associated with higher expression of those molecules are

more »

... production, IL12 pathway, TCR pathway and PD1 signalling among others; thus suggesting an immune modulation of the microenvironment that leads to a better prognosis. Conclusion The CMS4 subtype has usually higher risk of relapse comparing to other subtypes. However, segregating the group using specific immune biomarkers is able to identify patients with the significantly better survival.